MERUS N.V. reported on the nine months ended September 30, 2025, dominated by the announced acquisition by Genmab A/S and significant internal investment into its pipeline.
CRITICAL TRANSACTION: GENMAB ACQUISITION On September 29, 2025, Merus entered a definitive agreement whereby Genmab commenced a cash tender offer to acquire all outstanding shares for $97.00 per common share, leading to a potential delisting from Nasdaq. The transaction is subject to a minimum tender condition of 80% shareholder participation. Significant break fees are applicable: Merus owes Genmab $240.0M if Me
...